Datavant CEO Kyle Armbrester (L) and president Arnaub Chatterjee
May 15, 2025 08:30 AM EDT
Deals
AI

Ex­clu­sive: Data­vant to ac­quire re­al-world da­ta spe­cial­ist Ae­tion, dou­bling life sci­ences team

Andrew Dunn

Senior Biopharma Correspondent

The health tech com­pa­ny Data­vant is ac­quir­ing Ae­tion, a ri­val in the re­al-world da­ta space, End­points News ex­clu­sive­ly re­ports.

Data­vant on Thurs­day plans to an­nounce …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

TRENDING NOW

Bio­haven stock sinks on three-month de­lay for neu­ro drug's FDA ap­proval de­ci­sion

Ex­clu­sive: Drug com­pounder Em­pow­er was built on risky short­cuts, ex-em­ploy­ees and in­spec­tions al­lege

Up­dat­ed: Mer­ck KGaA con­tin­ues US tar­iff sur­charge but at a 'de­creased' rate 

Bris­tol My­ers CEO says Amer­i­ca’s bio­phar­ma pole po­si­tion is not guar­an­teed

Hen­grui, one of Chi­na's lead­ing biotechs, an­tic­i­pates $1.2B in pro­posed Hong Kong list­ing

FDA gives Ab­b­Vie ac­cel­er­at­ed ap­proval for an­ti­body-drug con­ju­gate in lung can­cer

A service from the Financial Times